• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Ceccacci Peter claimed ownership of 468,148 units of Common Stock; $0.0001 par value (SEC Form 3)

    5/1/26 5:44:49 PM ET
    $LABT
    Get the next $LABT alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Ceccacci Peter

    (Last)(First)(Middle)
    8031 COOPER CREEK BLVD UNIT 103

    (Street)
    UNIVERSITY PARK FLORIDA 34201

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/17/2026
    3. Issuer Name and Ticker or Trading Symbol
    Lakewood-Amedex Biotherapeutics Inc. [ LABT ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock; $0.0001 par value468,148D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Option (right to buy)03/01/202203/01/2031Common Stock33,784$2.78D
    Option (right to buy)03/02/202303/01/2033Common Stock67,568$2.13D
    Option (right to buy)03/02/202403/01/2033Common Stock50,676$2.13D
    Option (right to buy)03/14/202503/13/2034Common Stock29,561$2.13D
    Option (right to buy)07/02/202507/01/2035Common Stock202,703$2.31D
    Explanation of Responses:
    /s/ Peter Ceccacci05/01/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $LABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LABT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tucker Joseph Edward

    4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/6/26 6:20:17 PM ET
    $LABT

    New insider Tucker Joseph Edward claimed no ownership of stock in the company (SEC Form 3)

    3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/6/26 6:19:02 PM ET
    $LABT

    New insider Deroma Leonard James claimed ownership of 187,736 units of Common Stock; $0.0001 par value (SEC Form 3)

    3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/1/26 6:31:57 PM ET
    $LABT

    $LABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

    Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU programSARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabe

    6/25/26 8:02:00 AM ET
    $LABT

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

    New patent enhances global IP footprint and pipeline expansion opportunitiesSARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.

    6/22/26 8:02:00 AM ET
    $LABT

    $LABT
    SEC Filings

    View All

    SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

    424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    6/22/26 4:11:56 PM ET
    $LABT

    SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

    424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    6/22/26 4:10:35 PM ET
    $LABT

    Lakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    6/17/26 11:40:39 AM ET
    $LABT

    $LABT
    Leadership Updates

    Live Leadership Updates

    View All

    Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

    Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance

    4/28/26 7:33:00 AM ET
    $ENVB
    $LABT
    Biotechnology: Pharmaceutical Preparations
    Health Care